NLRP3 and metabolic dysfunction-associated steatotic liver disease: Apart from CAV1, additional chemical medicines, such as Berberine (BBR) and Salvianolic acid A (SalA), have been found to inhibit pyroptosis during the NAFLD process by modulating TXNIP-induced NLRP3 inflammasome activation [108, 109].